46. J Clin Invest. 2018 Apr 2;128(4):1671-1687. doi: 10.1172/JCI90277. Epub 2018 Mar 19.DNA repair deficiency sensitizes lung cancer cells to NAD+ biosynthesis blockade.Touat M(1)(2)(3), Sourisseau T(1), Dorvault N(1)(4), Chabanon RM(1)(4), GarridoM(1)(4), Morel D(1)(4), Krastev DB(5), Bigot L(1), Adam J(1)(6), Frankum JR(5),Durand S(7), Pontoizeau C(8)(9)(10), Souquère S(11), Kuo MS(1), Sauvaigo S(12),Mardakheh F(13), Sarasin A(14), Olaussen KA(1)(15), Friboulet L(1), BouillaudF(16), Pierron G(11), Ashworth A(17), Lombès A(16), Lord CJ(5), SoriaJC(1)(2)(15), Postel-Vinay S(1)(2)(4)(5).Author information: (1)Inserm U981, Gustave Roussy, Université Paris-Saclay, Villejuif, France.(2)Département d'Innovation Thérapeutique et d'Essais Précoces (DITEP), GustaveRoussy, Université Paris-Saclay, Villejuif, France.(3)Inserm U1127, CNRS UMR 7225, Sorbonne Universités, UPMC Université Paris 06UMRS1127, Institut du Cerveau et de la Moelle Epiniere, ICM, Paris, France.(4)Inserm U981, ATIP-Avenir Team, Gustave Roussy, Université Paris-Saclay,Villejuif, France.(5)The CRUK Gene Function Laboratory and Breast Cancer Now Research Centre, TheInstitute of Cancer Research, London, United Kingdom.(6)Département de Biologie et Pathologies Médicales, and.(7)Metabolomics Platform, Gustave Roussy, Université Paris-Saclay, Villejuif,France.(8)Centre de Référence des Maladies Héréditaires du Métabolisme, HôpitalNecker-Enfants Malades, Assistance Publique-Hôpitaux de Paris, Paris, France.(9)Service de Biochimie Métabolomique et Protéomique, Hôpital Necker-EnfantsMalades, Assistance Publique-Hôpitaux de Paris, Paris, France.(10)Inserm U1163, Institut Imagine, Equipe "Génétique des MaladiesMitochondriales" and Paris Descartes University, Paris, France.(11)CNRS UMR-9196, Functional Organization of the Cell, Gustave Roussy,Université Paris-Saclay, Villejuif, France.(12)LXRepair, Grenoble, France.(13)Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.(14)CNRS UMR-8200, Laboratory of Genetic Stability and Oncogenesis, GustaveRoussy, Université Paris-Saclay, Villejuif, France.(15)Faculté de médecine Paris-Sud XI, Kremlin-Bicêtre.(16)Inserm U1016, CNRS UMR 8104, Institut Cochin, UniversitéParis-Descartes-Paris 5, Paris, France.(17)UCSF Helen Diller Family Comprehensive Cancer Center, UCSF, San Francisco,USA.Synthetic lethality is an efficient mechanism-based approach to selectivelytarget DNA repair defects. Excision repair cross-complementation group 1 (ERCC1) deficiency is frequently found in non-small-cell lung cancer (NSCLC), making thisDNA repair protein an attractive target for exploiting synthetic lethalapproaches in the disease. Using unbiased proteomic and metabolic high-throughputprofiling on a unique in-house-generated isogenic model of ERCC1 deficiency, wefound marked metabolic rewiring of ERCC1-deficient populations, includingdecreased levels of the metabolite NAD+ and reduced expression of therate-limiting NAD+ biosynthetic enzyme nicotinamide phosphoribosyltransferase(NAMPT). We also found reduced NAMPT expression in NSCLC samples with low levels of ERCC1. These metabolic alterations were a primary effect of ERCC1 deficiency, and caused selective exquisite sensitivity to small-molecule NAMPT inhibitors,both in vitro - ERCC1-deficient cells being approximately 1,000 times moresensitive than ERCC1-WT cells - and in vivo. Using transmission electronicmicroscopy and functional metabolic studies, we found that ERCC1-deficient cells harbor mitochondrial defects. We propose a model where NAD+ acts as a regulatorof ERCC1-deficient NSCLC cell fitness. These findings open therapeuticopportunities that exploit a yet-undescribed nuclear-mitochondrial syntheticlethal relationship in NSCLC models, and highlight the potential for targetingDNA repair/metabolic crosstalks for cancer therapy.DOI: 10.1172/JCI90277 PMCID: PMC5873862PMID: 29447131 